Bio-Europe Spring Meeting Calling for Prime.io- Redefine Cell Line Engineering
Prime.io Ltd helps antibody and drug target validation teams to generate high-quality knock-in and knock-out cell models—fast. Powered by our proprietary AI designed CRISPR platform (commercial licence available), we deliver:
• 3x higher knock-in efficiency than conventional spCas9 in pool and single cancer/iPSC cell derived clone
• Up to 97% knock-out efficiency in single cancer/iPSC cell derived clone
• Reduced off-target activity and immunogenicity
• NGS-validated single-cell clones